th-302 has been researched along with Triple-Negative-Breast-Neoplasms* in 2 studies
2 other study(ies) available for th-302 and Triple-Negative-Breast-Neoplasms
Article | Year |
---|---|
Chitosan oligosaccharide decorated liposomes combined with TH302 for photodynamic therapy in triple negative breast cancer.
Triple negative breast cancer (TNBC) is an aggressive tumor with extremely high mortality that results from its lack of effective therapeutic targets. As an adhesion molecule related to tumorigenesis and tumor metastasis, cluster of differentiation-44 (also known as CD44) is overexpressed in TNBC. Moreover, CD44 can be effectively targeted by a specific hyaluronic acid analog, namely, chitosan oligosaccharide (CO). In this study, a CO-coated liposome was designed, with Photochlor (HPPH) as the 660 nm light mediated photosensitizer and evofosfamide (also known as TH302) as the hypoxia-activated prodrug. The obtained liposomes can help diagnose TNBC by fluorescence imaging and produce antitumor therapy by synergetic photodynamic therapy (PDT) and chemotherapy.. Compared with the nontargeted liposomes, the targeted liposomes exhibited good biocompatibility and targeting capability in vitro; in vivo, the targeted liposomes exhibited much better fluorescence imaging capability. Additionally, liposomes loaded with HPPH and TH302 showed significantly better antitumor effects than the other monotherapy groups both in vitro and in vivo.. The impressive synergistic antitumor effects, together with the superior fluorescence imaging capability, good biocompatibility and minor side effects confers the liposomes with potential for future translational research in the diagnosis and CD44-overexpressing cancer therapy, especially TNBC. Topics: Animals; Antineoplastic Agents; Chitosan; Female; Humans; Hyaluronan Receptors; Hyaluronic Acid; Liposomes; Mice; Mice, Inbred BALB C; Mice, Nude; Nanomedicine; Nitroimidazoles; Oligosaccharides; Optical Imaging; Phosphoramide Mustards; Photochemotherapy; Photosensitizing Agents; Prodrugs; Triple Negative Breast Neoplasms | 2021 |
Engineered Breast Cancer Cell Spheroids Reproduce Biologic Properties of Solid Tumors.
Solid tumors develop as 3D tissue constructs. As tumors grow larger, spatial gradients of nutrients and oxygen and inadequate diffusive supply to cells distant from vasculature develops. Hypoxia initiates signaling and transcriptional alterations to promote survival of cancer cells and generation of cancer stem cells (CSCs) that have self-renewal and tumor-initiation capabilities. Both hypoxia and CSCs are associated with resistance to therapies and tumor relapse. This study demonstrates that 3D cancer cell models, known as tumor spheroids, generated with a polymeric aqueous two-phase system (ATPS) technology capture these important biological processes. Similar to solid tumors, spheroids of triple negative breast cancer cells deposit major extracellular matrix proteins. The molecular analysis establishes presence of hypoxic cells in the core region and expression of CSC gene and protein markers including CD24, CD133, and Nanog. Importantly, these spheroids resist treatment with chemotherapy drugs. A combination treatment approach using a hypoxia-activated prodrug, TH-302, and a chemotherapy drug, doxorubicin, successfully targets drug resistant spheroids. This study demonstrates that ATPS spheroids recapitulate important biological and functional properties of solid tumors and provide a unique model for studies in cancer research. Topics: Antineoplastic Agents; Biomarkers, Tumor; Cell Engineering; Cell Line, Tumor; Doxorubicin; Drug Resistance, Neoplasm; Extracellular Matrix Proteins; Female; Humans; Hypoxia; Neoplastic Stem Cells; Nitroimidazoles; Phosphoramide Mustards; Polymers; Prodrugs; Spheroids, Cellular; Triple Negative Breast Neoplasms | 2016 |